JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“The pan-immune suppressive state generated during persistent infection closely resembles that observed in cancer ( 3 , 4 ), including T cell exhaustion and suppressive myeloid cells shared between cancer and persistent viral infection, which have led to fundamental discoveries such as T cell…”
BackgroundDetermining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986 · cited 1×
“…cancer ( 3 , 4 ), including T cell exhaustion and suppressive myeloid cells shared between cancer and persistent viral infection, which have led to fundamental discoveries such as T cell reactivation by PD-1 blockade in the lymphocytic choriomeningitis virus (LCMV) Clone 13 (Cl13) model ( 5 – 7 ).”
BackgroundSimultaneous epitope and transcriptome measurement in single cells
Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P. K., Swerdlow, H., Satija, R., & Smibert, P. (2017) · Nature Methods · doi:10.1038/nmeth.4380 · Cited by 3,098 · cited 2×
“To understand the basis of this beneficial effect, we isolated MC38 tumor-infiltrating cells from anti – PD-1+anti-CTLA4 – treated mice and analyzed single-cell transcriptomes and protein markers using CITE-seq ( 22 ).”
MethodTempleton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Granulocyticcellsin-cludeapopulationofpolymorphonuclear MDSCs(PMN-MDSCs),whichsharesurface markerswithneutrophils( 28 ).”
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940 · cited 6×
“Suppressive activity in myeloid cells can be acquired owing to excessive stimulation by soluble factors, including the JAK-signaling cytokines G-CSF and GM-CSF ( 9 , 30 , 31 ).”
BackgroundInfluentialThe JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · cited 1×
“Given the important role of JAK-STAT signaling in antigen presentation and T cell recruitment, complete ablation of JAK1 and JAK2 activity is unlikely to improve antitumor immunity or ICI response ( 39 , 51 ).”
BackgroundGreen, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · cited 3×
“Moreover, JAKis exert direct effects on cancer cells ( 27 ), dendritic cells ( 48 ), NK cells ( 49 ), T cells ( 50 ), and other cell types ( 23 ), suggesting a context-dependent overall impact of therapeutic JAK inhibition.”
BackgroundTolerance induction in double specific T-cell receptor transgenic mice varies with antigen
Pircher, H., Bürki, K., Lang, R., Hengartner, H., & Zinkernagel, R. M. (1989) · Nature · doi:10.1038/342559a0 · Cited by 1,019 · cited 1×
“P14micewere generatedbyPircher et al . and are available as Jackson Laboratory stock 37394 ( 71 ).”
BackgroundDGIdb 3.0: a redesign and expansion of the drug–gene interaction database
Cotto, K. C., Wagner, A. H., Feng, Y.-Y., Kiwala, S., Coffman, A. C., Spies, G., Wollam, A., Spies, N. C., Griffith, O. L., & Griffith, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1143 · Cited by 885 · cited 2×
“Using annotated compound gene interactions curated by the Drug-Gene Interaction Database ( 19 ), we found an enrichment of JAKis among the hits (fig.”
MethodQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843 · cited 1×
“We focused on ruxolitinib, the first JAKi to receive clinical approval ( 20 , 21 ) and currently in clinical use for indications including myelo-fibrosis and graft versus host disease ( 20 , 21 ).”
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791 · cited 1×
“Classic Hodgkin lymphoma is characterized by frequent alteration of chromosome 9p and exhibits JAK2 and CD274 (PD-L1) copy number changes ( 61 – 63 ).”
BackgroundArmand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Persistent LCMV infection is controlled by blockade of type I interferon signaling
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C. F., Welch, M., Schreiber, R. D., Carlos de la Torre, J., & Oldstone, M. B. A. (2013) · Science · doi:10.1126/science.1235214 · Cited by 755 · cited 1×
“S4, B and C) ( 24 , 25 ).”
Self-citationBlockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709
Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
Mulder, K., Patel, A. A., Kong, W. T., Piot, C., Halitzki, E., Dunsmore, G., Khalilnezhad, S., Irac, S. E., Dubuisson, A., Chevrier, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.007 · Cited by 678 · cited 2×
“To further understand the phenotypic characteristics of these clusters, we compared markers of human monocytes and macrophages in the MoMac-VERSE dataset ( 29 ).”
MethodMDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
The emerging safety profile of JAK inhibitors in rheumatic disease
Winthrop, K. L. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.23 · Cited by 590
Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.200939903 · Cited by 569 · cited 1×
“Suppressive activity in myeloid cells can be acquired owing to excessive stimulation by soluble factors, including the JAK-signaling cytokines G-CSF and GM-CSF ( 9 , 30 , 31 ).”
BackgroundMyeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538 · cited 1×
“Suppressive myeloid cells are present in many tumor types and cause lymphocyte dysfunction and poor response to checkpoint inhibitor immuno-therapy ( 1 , 2 ).”
BackgroundAlshetaiwi, H., Pervolarakis, N., McIntyre, L. L., Ma, D., Nguyen, Q., Rath, J. A., Nee, K., Hernandez, G., Evans, K., Torosian, L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay6017 · Cited by 537 · cited 1×
“4F) ( 9 , 33 ).”
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521 · cited 1×
“Clinical responses were evaluated by positron emission tomography (PET) or computed tomography (CT) scan at 1, 3, 6, 9, 12, 18, and 24 months using the Lugano criteria adapted to immune-based therapy, LYRIC ( 40 ).”
MethodJanus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501 · cited 1×
“Several small-molecule JAKis have been ap-provedintheclinicandare predominantly used to treat myeloproliferative and autoimmune diseases ( 17 ).”
BackgroundType I Interferon in Chronic Virus Infection and Cancer
Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 500
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480
Battegay, M., Cooper, S., Althage, A., Bänziger, J., Hengartner, H., & Zinkernagel, R. M. (1991) · Journal of Virological Methods · doi:10.1016/0166-0934(91)90018-u · Cited by 475 · cited 1×
“10 m l of serum was used to perform 10-fold serial dilutions and quantified by focus forming assay on VeroE6 cells as previously described ( 73 ).”
MethodMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Grieshaber-Bouyer, R., Radtke, F. A., Cunin, P., Stifano, G., Levescot, A., Vijaykumar, B., Nelson-Maney, N., Blaustein, R. B., Monach, P. A., Nigrovic, P. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22973-9 · Cited by 344 · cited 2×
“S9E) ( 32 ).”
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Heine, A., Held, S. A. E., Daecke, S. N., Wallner, S., Yajnanarayana, S. P., Kurts, C., Wolf, D., & Brossart, P. (2013) · Blood · doi:10.1182/blood-2013-03-484642 · Cited by 344 · cited 1×
“Moreover, JAKis exert direct effects on cancer cells ( 27 ), dendritic cells ( 48 ), NK cells ( 49 ), T cells ( 50 ), and other cell types ( 23 ), suggesting a context-dependent overall impact of therapeutic JAK inhibition.”
BackgroundSacdalan, D. B., Lucero, J. A., & Sacdalan, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 306 · cited 1×
“However, NLR is also associated with anti – PD-1 response in other tu-mortypes,includingmelanomaandlungcancer ( 68 , 69 ).”
BackgroundExploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
Howard, R., Kanetsky, P. A., & Egan, K. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56218-z · Cited by 296 · cited 1×
“The neutrophil-to-lymphocyte ratio (NLR), clinically known to correlate with MDSC fre-quencyandpoor prognosisacrosscancer types including Hodgkin lymphoma ( 41 – 44 ), showed a significant reduction postruxolitinib (Fig.”
BackgroundGreene, S., Robbins, Y., Mydlarz, W. K., Huynh, A. P., Schmitt, N. C., Friedman, J., Horn, L. A., Palena, C., Schlom, J., Maeda, D. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2625 · Cited by 280 · cited 1×
“…the CD11b + Gr1 + magneticisolation kit (STEM-CELL Technologies cat #19867) and incubated with NK cells isolated using the mouse NK cell isolation kit (STEMCELL Technologies cat #19855) from tumor-free wild-type B6 mice in the indicated ratios in the presence of IL-2 as described previously ( 77 ).”
MethodPardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 264
Ramchandren, R., Domingo-Domènech, E., Rueda, A., Trněný, M., Feldman, T. A., Lee, H. J., Provencio, M., Sillaber, C., Cohen, J. B., Savage, K. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00315 · Cited by 252 · cited 1×
“Classic Hodgkin lymphoma is characterized by frequent alteration of chromosome 9p and exhibits JAK2 and CD274 (PD-L1) copy number changes ( 61 – 63 ).”
BackgroundRuxolitinib‐associated infections: A systematic review and meta‐analysis
Lussana, F., Cattaneo, M., Rambaldi, A., & Squizzato, A. (2018) · American Journal of Hematology · doi:10.1002/ajh.24976 · Cited by 250 · cited 1×
“Previously, reports showed that PD-1 inhibition can be effective in individual patients treated with ruxolitinib ( 54 , 55 ) despite the general immunosuppressive effects of ruxoli-tinib ( 56 , 57 ).”
BackgroundSystematic investigation of cytokine signaling activity at the tissue and single-cell levels
Jiang, P., Zhang, Y., Ru, B., Yang, Y., Vu, T., Paul, R., Mirza, A., Altan-Bonnet, G., Liu, L., Ruppin, E., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01274-5 · Cited by 244 · cited 1×
“S10A) ( 38 ).”
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Mathew, D., Marmarelis, M. E., Foley, C., Bauml, J. M., Ye, D., Ghinnagow, R., Ngiow, S. F., Klapholz, M., Jun, S., Zhang, Z., et al. (2024) · Science · doi:10.1126/science.adf1329 · Cited by 232 · cited 1×
“Indeed, combination therapy of the JAKi itacitinib with the anti – PD-1 antibody pembrolizumab in non – small-cell lung cancer showed an encouraging 67% overall response rate in a phase II clinical trial published jointly with this article ( 70 ).”
BackgroundVan Rompaey, L., Galien, R., van der Aar, E. M., Clement-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 231
Janes, J. O., Young, M. E., Chen, E., Rogers, N. H., Burgstaller-Muehlbacher, S., Hughes, L. D., Love, M. S., Hull, M. V., Kuhen, K., Woods, A. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810137115 · Cited by 218 · cited 2×
“To obtain drug gene interactions, ChEMBL IDs were first retrieved using the ChEMBL API (Plate list of compounds in the ReFrame library ( 74 ) was filtered for duplicates such that only a single plate well per unique molecule was included.”
BackgroundMethodMechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 207 · cited 2×
“Moreover, JAKis exert direct effects on cancer cells ( 27 ), dendritic cells ( 48 ), NK cells ( 49 ), T cells ( 50 ), and other cell types ( 23 ), suggesting a context-dependent overall impact of therapeutic JAK inhibition.”
BackgroundParallels between Cancer and Infectious Disease
Hotchkiss, R. S., & Moldawer, L. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1404664 · Cited by 201 · cited 1×
“The pan-immune suppressive state generated during persistent infection closely resembles that observed in cancer ( 3 , 4 ), including T cell exhaustion and suppressive myeloid cells shared between cancer and persistent viral infection, which have led to fundamental discoveries such as T cell…”
BackgroundJAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3198 · Cited by 181 · cited 1×
“Moreover, JAKis exert direct effects on cancer cells ( 27 ), dendritic cells ( 48 ), NK cells ( 49 ), T cells ( 50 ), and other cell types ( 23 ), suggesting a context-dependent overall impact of therapeutic JAK inhibition.”
BackgroundLu, C., Talukder, A., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176 · cited 1×
“This is supported by observations in other studies in which T cell function was preserved at therapeutic doses of JAKis, including pre-served graft-versus-tumor effect in ruxolitinib-treated graft-versus-host disease ( 52 , 53 ).”
ResultJAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
Parampalli Yajnanarayana, S., Stübig, T., Cornez, I., Alchalby, H., Schönberg, K., Rudolph, J., Triviai, I., Wolschke, C., Heine, A., Brossart, P., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13373 · Cited by 162
Norris, B. A., Uebelhoer, L. S., Nakaya, H. I., Price, A. A., Grakoui, A., & Pulendran, B. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.022 · Cited by 160
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Albeituni, S., Verbist, K., Tedrick, P., Sheppard, H., Picarsic, J. L., Bassett, R., & Nichols, K. E. (2019) · Blood · doi:10.1182/blood.2019000761 · Cited by 160
Hwang, M., Canzoniero, J. V., Rosner, S., Zhang, G., White, J. R., Belcaid, Z., Cherry, C., Balan, A., Pereira, G., Curry, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004688 · Cited by 150
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1409 · Cited by 146 · cited 4×
“S11A) ( 39 ), we observed an increase in the percentage of moDCs in tumors of ICI+ ruxolitinib – versus ICI-treated mice with single-cell transcriptomics (fig.”
BackgroundMethodInfluentialCader, F. Z., Hu, X., Goh, W. L., Wienand, K., Ouyang, J., Mandato, E., Redd, R., Lawton, L. N., Chen, P.-H., Weirather, J. L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1006-1 · Cited by 142
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
Wu, S.-C., Li, L. S., Kopp, N., Montero, J., Chapuy, B., Yoda, A., Christie, A. L., Liu, H., Christodoulou, A. N., van Bodegom, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.005 · Cited by 135
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 130 · cited 1×
“Suppressive myeloid cells are present in many tumor types and cause lymphocyte dysfunction and poor response to checkpoint inhibitor immuno-therapy ( 1 , 2 ).”
BackgroundPotent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Baffert, F., Régnier, C. H., De Pover, A., Pissot-Soldermann, C., Tavares, G. A., Blasco, F., Brueggen, J., Chène, P., Drueckes, P., Erdmann, D., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0053 · Cited by 120
Oxenius, A., Bachmann, M. F., Ashton‐Rickardt, P. G., Tonegawa, S., Zinkernagel, R. M., & Hengartner, H. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251230 · Cited by 117 · cited 1×
“…× 10 5 cells/well in complete T cell media(10%FBS,L-glutamine,Pen/Strep,NEAA, SodiumPyruvate,HEPES, b -mercaptoethanol) supplemented with a cocktail of all known immunodominant LCMV CD8-specific (LCMV-GP33-41,LCMV-GP276-286,andLCMV-NP396-404)andCD4-specific(LCMV-GP61-80)epitope peptides( 75 , 76 ).”
MethodGairin, J. E., Mazarguil, H., Hudrisier, D., & Oldstone, M. B. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2297-2305.1995 · Cited by 116 · cited 1×
“…× 10 5 cells/well in complete T cell media(10%FBS,L-glutamine,Pen/Strep,NEAA, SodiumPyruvate,HEPES, b -mercaptoethanol) supplemented with a cocktail of all known immunodominant LCMV CD8-specific (LCMV-GP33-41,LCMV-GP276-286,andLCMV-NP396-404)andCD4-specific(LCMV-GP61-80)epitope peptides( 75 , 76 ).”
MethodSelf-citationLymphocytic Choriomeningitis Virus (LCMV): Propagation, Quantitation, and Storage
Welsh, R. M., & Seedhom, M. O. (2008) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc15a01s8 · Cited by 104 · cited 1×
“LCMV Cl13 was passaged on BHK-21 cells as previously reported ( 72 ).”
MethodXiao, W. L., Klement, J. D., Lu, C., Ibrahim, M. L., & Liu, K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800129 · Cited by 96 · cited 1×
“Therapeutics specifically targeting these cells have yet to gain clinical approval ( 12 ), and conflicting effects of JAK inhibitors (JAKis) on MDSCs have been reported ( 13 – 15 ).”
BackgroundIto, M., Yamazaki, S., Yamagami, K., Kuno, M., Morita, Y., Okuma, K., Nakamura, K., Chida, N., Inami, M., Inoue, T., et al. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.001 · Cited by 96
Rudd, C. E., Chanthong, K., & Taylor, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.076 · Cited by 77
Tavakkoli, M., Wilkins, C. R., Mones, J. V., & Mauro, M. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00295 · Cited by 69 · cited 1×
“The neutrophil-to-lymphocyte ratio (NLR), clinically known to correlate with MDSC fre-quencyandpoor prognosisacrosscancer types including Hodgkin lymphoma ( 41 – 44 ), showed a significant reduction postruxolitinib (Fig.”
BackgroundSendo, S., Saegusa, J., Yamada, H., Nishimura, K., & Morinobu, A. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1963-2 · Cited by 68 · cited 1×
“JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ).”
BackgroundRomano, A., Parrinello, N. L., Vetro, C., Chiarenza, A., Cerchione, C., Ippolito, M., Palumbo, G. A., & Raimondo, F. D. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3276-y · Cited by 68 · cited 1×
“The immune-modulating effect of ruxolitinib when combined with ICI in Hodgkin lymphoma patients can abrogate a negative prognostic relevance of NLR for progression-free survival (PFS) ( 43 , 67 ) and negative prognostic relevance of monocytes for nivolumab response.”
BackgroundCurtis, V. F., Wang, H., Yang, P., McLendon, R. E., Li, X., Zhou, Q., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054916 · Cited by 63 · cited 1×
“4F) ( 34 – 37 ).”
CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma
Yoon, D. H., Koh, Y. W., Kang, H. J., Kim, S., Park, C. S., Lee, S., Suh, C., & Huh, J. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01731.x · Cited by 62 · cited 1×
“CD163 is a gene associated with tumor-associated macrophages, and its expression has been associated with high-risk Hodgkin lymphoma ( 64 , 65 ).”
BackgroundImproving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C., Spilgies, L., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 61 · cited 1×
“JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ).”
BackgroundKoh, Y. W., Park, C. S., Yoon, D. H., Suh, C., & Huh, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087066 · Cited by 59 · cited 1×
“CD163 is a gene associated with tumor-associated macrophages, and its expression has been associated with high-risk Hodgkin lymphoma ( 64 , 65 ).”
BackgroundIdentification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression
Abrams, S. I., & Waight, J. D. (2012) · OncoImmunology · doi:10.4161/onci.19334 · Cited by 54 · cited 1×
“Suppressive activity in myeloid cells can be acquired owing to excessive stimulation by soluble factors, including the JAK-signaling cytokines G-CSF and GM-CSF ( 9 , 30 , 31 ).”
BackgroundDiscovery of Small Molecules for the Reversal of T Cell Exhaustion
Marro, B. S., Žák, J., Zavareh, R. B., Teijaro, J. R., Lairson, L. L., & Oldstone, M. B. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.119 · Cited by 50 · cited 2×
“An assay using a YFP – IFN-g reporter strain was ( 18 ).”
MethodSelf-citationKim, S. J., Yoon, D. H., Kang, H. J., Hong, J. Y., Lee, H. S., Oh, S. Y., Shin, H., Kong, J. H., Yi, J. H., Sakamoto, K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6303-z · Cited by 34 · cited 1×
“The favorable response rate of this combination contrasts with the limited efficacy of ruxolitinib monotherapy in R/R classic Hodgkin lymphoma ( 58 – 60 ).”
ResultMalignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells
Rajappa, P., Cobb, W. S., Vartanian, E. D., Huang, Y., Daly, L., Hoffman, C. E., Zhang, J., Shen, B., Yanowitch, R. N., Garg, K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1508 · Cited by 27 · cited 1×
“JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ).”
BackgroundBMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
Pardanani, A. D., Roberts, A. W., Seymour, J. F., Burbury, K., Verstovšek, S., Kantarjian, H. M., Begna, K. H., Yoshitsugu, H., Gestone, T. A., Phillips, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.664.664 · Cited by 25
Yu, B., Yang, L., Song, S., Li, W., Wang, H., & Cheng, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00517.2020 · Cited by 24 · cited 1×
“4F) ( 34 – 37 ).”
Cardot‐Ruffino, V., Böllenrücher, N., Delius, L., Wang, S. J., Brais, L. K., Remland, J., Keheler, C. E., Sullivan, K. M., Abrams, T. A., Biller, L. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006589 · Cited by 23 · cited 2×
“…and activator of transcription (STAT) transcription factors and the Januskinase(JAK)1and2 – dependentcytokines granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophagecolony-stimulatingfac-tor(GM-CSF),andinterleukin-6(IL-6)areim-plicatedinsuppressiveprogrammingofMDSCs ( 9 – 11 ).”
BackgroundSimon, N. C., Antignani, A., Hewitt, S. M., Gadina, M., Alewine, C., & FitzGerald, D. J. (2019) · JCI Insight · doi:10.1172/jci.insight.123281 · Cited by 23 · cited 1×
“JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ).”
Backgroundde Lima, C. B., Tamura, E. K., Montero‐Melendez, T., Palermo‐Neto, J., Perretti, M., Markus, R. P., & Farsky, S. H. P. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.078 · Cited by 22
Maenhout, S. K., Four, S. D., Corthals, J., Neyns, B., Thielemans, K., & Aerts, J. L. (2014) · Oncotarget · doi:10.18632/oncotarget.2254 · Cited by 18 · cited 2×
“JAKis target pathways directly involved in the suppressive programming of MDSCs ( 10 ); however, JAKis have been reported to promote ( 13 , 14 , 45 ) or restrain MDSC function or migration depending on the disease model ( 46 , 47 ).”
BackgroundRomano, A., Pavoni, C., Raimondo, F. D., Tarella, C., Viviani, S., Rossi, A., Patti, C., Picardi, M., Cantonetti, M., Nasa, G. L., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3396 · Cited by 14
Nivolumab combined with ruxolitinib: antagonism or synergy?
Debureaux, P.-É., Arrondeau, J., Bouscary, D., & Goldwasser, F. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy077 · Cited by 14 · cited 1×
“Previously, reports showed that PD-1 inhibition can be effective in individual patients treated with ruxolitinib ( 54 , 55 ) despite the general immunosuppressive effects of ruxoli-tinib ( 56 , 57 ).”
BackgroundPan, B., Shang, L., Liu, C., Gao, J., Zhang, F., Xu, M., Li, L., Sun, Z., Li, Z., & Xu, K. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16275 · Cited by 11 · cited 1×
“This is supported by observations in other studies in which T cell function was preserved at therapeutic doses of JAKis, including pre-served graft-versus-tumor effect in ruxolitinib-treated graft-versus-host disease ( 52 , 53 ).”
Result
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Kureshi, C. T., & Dougan, S. K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.11.011 · Cited by 213
Metadata
- Authors
- Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., Varner, J. A., Hegerova, L., Cao, Q., Farooq, U., Kenkre, V. P., Bachanova, V., & Teijaro, J. R.
- Venue
- Science
- Published
- 2024-06-21
- Volume
- 384
- Issue
- 6702
- Pages
- eade8520-eade8520
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4399848851
- Cited by
- 193
- References
- 88
- FWCI
- 29.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.